Duarte, CA – Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have discovered a new cellular mechanism that plays an important role in cancer cells’ ability to cause disease. The study was published in Nature Structural & Molecular Biology today....
Latest News
LOS ANGELES, Calif. — City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare...
Duarte, California – Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood published the preclinical findings today. By overcoming challenges, such as drug resistance and...
LOS ANGELES, Calif. — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, is part of today’s press conference program at the American Society for Radiation...
LOS ANGELES, Calif. — A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published today in Nature...
CAMBRIDGE, Mass. — City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, presented preclinical data for CITY-RBP4, a potentially first-in-class RNAi therapy for the treatment of Stargardt disease, in an oral session today at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual...
COLUMBUS, Ohio — Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced positive topline data from a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy, CMTX-101, in the treatment of people with cystic fibrosis (pwCF). These...
ALISO VIEJO, Calif. — Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the launch of a new gene mutation test that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC)....
Zürich, Switzerland – Patients with Guillain-Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness. In Europe and the USA, around 1 to 2 cases per 100,000 people occur every year. GBS usually begins...
SEATTLE, WA – Detecting malaria in people who aren’t experiencing symptoms is vital to public health efforts to better control this tropical disease in places where the mosquito-borne parasite is common. Asymptomatic people harboring the parasite can still transmit the disease or become ill later, after initially testing negative. The...